BioCentury | Apr 8, 2013
Company News

SK Chemicals, TheraVida deal

...TheraVida granted SK Chemicals exclusive rights to develop and commercialize Tolenix ( THVD-201 ) and THVD-202...
...royalties. TheraVida declined to disclose details, and SK Chemicals could not be reached for details. Tolenix...
...development for the indications. TheraVida said it is pursuing an international Phase III program for Tolenix...
BioCentury | Mar 25, 2013
Clinical News

Tolenix: Additional Phase II data

...data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix...
...episodes per day, both co-primary endpoints, vs. placebo (p<0.0001 for both). On a secondary endpoint, Tolenix...
...NYSE:PFE, New York, N.Y.) markets Detrol. TheraVida Inc. , Mountain View, Calif. Product: Tolenix ( THVD-201...
BioCentury | Jan 7, 2013
Clinical News

Tolenix: Phase II data

...data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix...
...endpoints of reducing urination frequency and the number of incontinence episodes per day vs. placebo. Tolenix...
...NYSE:PFE, New York, N.Y.) markets Detrol. TheraVida Inc. , Mountain View, Calif. Product: Tolenix ( THVD-201...
BioCentury | Jan 5, 2013
Clinical News

TheraVida's Tolenix meets in Phase II for OAB

...TheraVida Inc. (Mountain View, Calif.) said twice-daily Tolenix met the co-primary endpoints of reducing urination frequency...
...placebo in a Phase II trial to treat overactive bladder (OAB) and urge urinary incontinence. Tolenix...
...with Tolenix in patients with OAB and urge urinary incontinence, but declined to disclose details. Tolenix...
BioCentury | May 23, 2011
Clinical News

THVD-201: Phase II started

...double-blind, placebo-controlled, crossover, international Phase II trial in 120 female patients to compare 2 mg THVD-201...
...mg Detrol LA tolterodine tartrate for 16 weeks. Patients will have the option to continue THVD-201...
...Inc. (NYSE:PFE, New York, N.Y.) markets Detrol LA. TheraVida Inc , Mountain View, Calif. Product: THVD-201...
BioCentury | Apr 4, 2011
Clinical News

THVD-201: Phase I data

...An Australian Phase I trial in 17 healthy volunteers showed that THVD-201 was safe and improved...
...presented at the European Association of Urology meeting in Vienna. A Phase II trial of THVD-201...
...is ongoing with final data expected in 1Q12. TheraVida Inc , Mountain View, Calif. Product: THVD-201...
Items per page:
1 - 6 of 6